Tech & AI
Alphabet's Isomorphic Labs Raises $5bn Series C, Then Signs Merck Oncology Deal
The AI drug-discovery group raised a second multibillion-dollar round in six months and added a big-pharma partner two days later.
HedgeWeekly Tech & AI Desk ·
Isomorphic Labs, the London-based AI drug-discovery company spun out of Google DeepMind, has raised $5bn in a Series C round, according to coverage dated 17 November. Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz also taking part. Alphabet made what Fierce Biotech called a significant investment, and existing backers including Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund returned.
It is the company's second multibillion-dollar raise in about six months, following a $2.1bn Series B in May. City AM puts Isomorphic's disclosed outside funding since 2025 at roughly $7.7bn. The company has not disclosed a valuation for the new round; City AM noted that reports the previous month had pointed to a target of up to $50bn, against about $17.5bn before. Proceeds are earmarked for its drug-design engine, known as IsoDDE, its early-stage drug pipeline and clinical-development infrastructure.
Two days later Isomorphic announced a research collaboration with Merck in oncology, per Drug Discovery Trends. Merck datasets will feed IsoDDE to design small-molecule drug candidates against a single cancer target. Isomorphic will receive an upfront payment and could earn milestones and tiered royalties, while Merck handles preclinical and clinical development and any manufacturing and marketing. No financial terms were disclosed. Isomorphic remains in late-stage preclinical work and has not yet dosed patients.
Why it matters: the round is among the largest ever for a private European technology company and signals that investors are still funding AI beyond chatbots and data centres, with drug discovery as a test of whether models can deliver real products. For Alphabet, it adds to a stake in a business outside advertising and cloud. Watch for the first human trials, which Drug Discovery Trends said have slipped to the end of 2026, and for whether upfront payments in such partnerships grow; the article cites McKinsey figures showing only about 2% of headline deal value in recent AI drug-discovery pacts was paid up front.